PSK 3471

Drug Profile

PSK 3471

Alternative Names: PSK-3471; SERM-3471

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator ProSkelia; sanofi-aventis
  • Developer Galapagos NV
  • Class Osteoporosis therapies
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 24 Mar 2004 Phase-II clinical trials in Postmenopausal osteoporosis prevention in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top